To investigate whether the association between the metabolic syndrome (MS) and cardiovascular disease (CVD) in obese adults is influenced by the criteria used to diagnose the MS. DESIGN AND SUBJECTS: Cross-sectional study in 389 obese adults (male/female: 26%/74%; body mass index (BMI): 30.1-63.2 kg/m 2 ; age: 18-79 y). MEASUREMENTS: To diagnose the MS by the WHO or the ATPIII criteria, body mass index, waist circumference, fasting and 2-h oral Glucose tolerance test plasma glucose, fasting plasma triglycerides and HDL cholesterol, systolic and diastolic blood pressure, 24-h albumin excretion, and fasting insulin were measured. The association between the MS diagnosed with either definition and self-referred CVD was investigated. RESULTS: The prevalence of the MS by the WHO was higher than by the ATPIII criteria (WHO 69.1%, ATPIII 49.4%; Po0.001). The MS diagnosed by the WHO criteria was significantly associated with self-referred CVD (odds ratio (OR) 5.80, 95% CI 1.35-24.95, Po0.05), whereas the ATPIIII MS was not (OR 1.34, 95% CI 0.59-3.03). An elevated blood pressure (OR 5.04, 95% CI 1.41-18.01, Po0.05) and microalbuminuria (OR 2.61, 95% CI 1.06-6.40, Po0.05) were independently associated with CVD. Consideration of the OGTT data as part of the ATPIII MS definition improved its associations with CVD (OR 4.39, Po0.05). CONCLUSION: The WHO criteria appear to identify a greater number of obese adults at risk for CVD. Nevertheless, the addition of an OGTT at least in nondiabetic patients with two ATPIII-defined metabolic risk factors may help to improve the association between the MS and CVD in obese adults.
Introduction
The concept of metabolic syndrome (MS) includes a constellation of laboratory and physical findings such as obesity, insulin resistance, glucose intolerance, hypertension, high triglycerides, and low HDL cholesterol. 1 It has been shown that subjects with the MS are at increased risk for cardiovascular disease (CVD) and mortality from both CVD and all causes. [2] [3] [4] However, the estimation of the strength of the association between the MS and cardiovascular morbidity and mortality is complicated by the lack of a standard definition of the MS. The World Health Organization (WHO) proposed a working definition of the MS based on the presence of insulin resistance and/or impaired glucose tolerance as an obligatory criterion, plus the coexistence of two additional commonly associated metabolic abnormalities. 5 More recently, the Third Report of the National Cholesterol Education Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III-ATPIII) provided new definition of the MS that is easier to use in the clinical setting. 6 Although similarities between the two proposed definitions exist, some of the defining features and the cutoff values for the different variables differ between the two sets of criteria. Therefore, not only the prevalence estimates of the MS but also its degree of association with CVD may vary depending on the definition used. 2, 7, 8 In the present study, we aimed to examine the association between the MS and CVD in obese adults using the two above-mentioned definitions of the MS. Obesity and the MS frequently coexist. 9, 10 Furthermore, it has been suggested that obesity may precede the development of other MS components. 6, 11 Moreover, both conditions are associated with CVD. [2] [3] [4] 12 However, few studies on the MS have specifically evaluated patients with a body mass index (BMI) above 30 kg/m. 2, 9, 10 The recent proposal that the MS but not BMI predicts future cardiovascular risk in women 13 underscores the relevance of understanding how to best define the cluster of cardiovascular risk factors that confer an increased cardiovascular risk to obese individuals. Clinical and biochemical parameters Body weight was measured in light clothing and without shoes to the nearest 0.1 kg. Height was measured to the nearest half centimetre. BMI was calculated as weight in kilograms divided by height in metres squared. Waist circumference was measured at the level of the iliac crest at minimal respiration to the nearest 0.5 cm. Three blood pressure readings were obtained at 1-min intervals and the second and third reading were averaged and used in the analysis. 15 Venous blood was collected after an overnight fast. Plasma glucose was measured using a glucose oxidase method (Bayer Diagnostics, Munich, Germany). An oral glucose tolerance test (OGTT, 75 g glucose) was performed in all patients that had not been previously diagnosed with diabetes, and each patient glucose tolerance was categorized according to the WHO criteria. 16 Total and HDL cholesterol and triglycerides were measured using a commercial enzymatic colorimetric kit (Bayer Diagnostics, Munich, Germany). Insulin levels were measured by monoclonal immunoradiometric assay (IRMA; Medgenix Diagnostics, Fleunes, Belgium). The intraassay and interassay coefficient of variation were o5 and o7%, respectively. Data from insulin and glucose concentration were used to estimate insulin sensitivity in subjects that had not previously been diagnosed with diabetes by calculating the homeostasis model assessment insulin resis- , (4) microalbuminuria: urinary albumin excretion rate Z20 mg/min. Since the measurement of the hip circumference was not available, waist circumference was considered as the surrogate for central fat distribution when the WHO MS criteria were applied. According to ATP III criteria, 6 the MS was considered when three or more of the following criteria were present: (1) abdominal obesity: waist circumference 4102 cm in male and 488 cm in female subjects; (2) hypertriglyceridemia: Z150 mg/dl; (3) low HDL cholesterol: o40 mg/dl in male and o50 mg/dl in female subjects; (4) elevated blood pressure: Z130/Z85 mmHg; (5) fasting hyperglycemia: fasting plasma glucose Z110 mg/dl. All subjects with previous diagnosis of diabetes or hypertension were considered to fit the respective criteria independently of the measured values. A metabolic syndrome score was calculated as the number of constituents of the MS present in each subject. 18 Accordingly, the MS score ranged from 1 (obesity and no additional MS component) to 5 (presence of all five components of the MS definition). CVD was considered to be present based on the clinical history. 7 Participants were considered to have CVD if they responded affirmatively to separate questions about whether they had ever been told by a doctor that they had coronary heart disease, ischaemic stroke, or peripheral vascular disease.
Methods

Subjects
Statistical analysis
All data are expressed as mean7standard error of the mean (s.e.m.). Comparisons between groups were performed using the w 2 , Mann-Whitney U, or analysis of variance (ANOVA) The prevalence of self-reported CVD was 6.4% (n ¼ 25). Patients with CVD were older (CVD positive: 57.6710.4 y, CVD negative: 45.8713.2 y; Po0.001), and had a higher prevalence of previously diagnosed hypertension (CVD positive: 80.0%, CVD negative 43.9%; Po0.001) or dyslipidemia (CVD positive: 60.0%, CVD negative: 25.2%; Po0.001). An increased number of altered constituents of the MS was associated with an increase in the mean value of systolic and diastolic blood pressure, plasma triglycerides, plasma HDL cholesterol, fasting plasma glucose, OGTT 2-h plasma glucose, and HOMA-IR (Tables 1  and 2 ). Consistently, a significant correlation was found between the MS score and these cardiovascular risk factors included in either the WHO or the ATP III definitions (Table 3) . Correlation analysis between waist circumference and MS score calculated either from the ATPIII criteria or the WHO criteria was statistically significant (Table 3) . However, correlation analysis between BMI and the MS score calculated from any of the two MS definitions yielded negative results.
Using the WHO definition, the prevalence of CVD was significantly higher among those with the MS compared to their MS negative counterparts (odds ratio (OR) 5.80, 95% CI 1.35-24.95, Po0.05; Figure 1) . Accordingly, the MS score Obesity, metabolic syndrome and cardiovascular disease J Vidal et al calculated from the WHO criteria was higher in subjects with self-reported CVD (CVD positive: 3.6470.99, CVD negative 3.0371.07; Po0.01). In sharp contrast, the prevalence of CVD was not significantly different between those with or without the MS when the ATPIII definition was applied (OR 1.34, 95% CI 0.59-3.03, P ¼ 0.485; Figure 1) . Likewise, the MS score calculated from the ATPIII criteria did not differ between those with or without CVD (2.7671.01 vs 2.5571.01; P ¼ 0.300). Among the 25 subjects with selfreported CVD, the diagnosis of the MS was concordant in 16 (64%). Two patients that self-referred CVD were not diagnosed as having the MS by neither of the two definitions. Nine (16%) subjects with CVD were identified as having the MS by the WHO definition, but not the ATP definition. In contrast, none was identified as having the MS by the ATPIII, but not the WHO criteria. According to Landis and Koch scale, the concordance rate in the diagnosis of the MS by the two sets of criteria among patients with CVD was not significant (k coefficient: 0.199; P ¼ 0.096). Logistic regression analysis with CVD as the dependent variable showed that a blood pressure or a microalbuminuria above the WHO cutoff values were independently associated with CVD (Table 4) . However, logistic regression analysis did not identify a single cardiovascular risk factor as independently associated with CVD when the MS ATPIII criteria were analysed. Finally, we aimed to assess whether the consideration of other glucose tolerance status or insulin sensitivity would improve the association between the ATPIII MS and CVD. Among subjects with a fasting plasma glucose r110 mg/dl and not previously diagnosed with diabetes, the analysis of the OGTT data led to the identification of an additional number of 104 subjects with newly diagnosed impaired glucose tolerance or type 2 diabetes. The consideration of these glucose tolerance categories as equivalents to impaired fasting glucose resulted in an increase in the prevalence of the MS according to the ATPIII definition from 49.4 to 64.3% (Po0.001). Interestingly, the diagnosis of the MS by means of these modified ATPIII criteria was significantly associated with an increased prevalence of self-referred CVD (MS positive: 8.8%, MS negative: 2.2%, Po0.01; OR 4.39, 95% CI 1.29-14.94, Po0.05). Logistic regression analysis with CVD as the dependent variable showed that among the MS criteria in the modified ATPIII definition, an altered glucose tolerance was independently associated with CVD (OR 2.84, 95% CI 1.00-8.10, P ¼ 0.05). Moreover, such a modification resulted in an improvement in the agreement in the diagnosis of the MS by the WHO and the ATPIII criteria among subjects with CVD (concordant diagnosis in 83.2% of subjects, k coefficient ¼ 0.627, Po0.001). The consideration of insulin resistance (estimated from fasting plasma glucose and insulin levels and defined as a HOMA-IR index above the 80th percentile of the reference population) as equivalent to impaired fasting glucose also resulted in an increase in the percentage of patients identified as having the MS by the ATPIII criteria (73.3%, Po0.001). Nevertheless, such a modification of the ATPIII criteria for the definition of the MS did not result in a significant association between the metabolic disturbances and CVD (MS positive: 7.4%, MS negative: 3.8%, P ¼ 0.250; OR 2.00, 95% CI 0.67-5.96, P ¼ 0.215). Obesity, metabolic syndrome and cardiovascular disease J Vidal et al
Discussion
The main finding of the present study is that the association between the MS and CVD in obese adults depends on the criteria used to identify subjects with the MS. Although the diagnosis of the MS was concordant by the two MS definitions in a significant proportion of individuals, the estimation of the strength of the association between the MS and CVD was stronger when the diagnosis of the MS was based on the WHO criteria. Obesity is currently viewed as a CVD risk factor. It is noteworthy that this is because obesity raises the risk other CVD risk factors that often cluster in a particular subject and make up the metabolic syndrome. 20 The recent demonstration that the diagnosis of the MS is more valuable than the measurement of BMI alone 13 underscores the importance of using a definition of the MS that best ascertains the CVD risk in obese subjects. Previous studies in different populations have shown that the MS diagnosed either by the WHO or the ATPIII definitions is associated with an increased CVD risk. [2] [3] [4] However, the influence of the utilization of a particular definition of the MS on the strength of this association has seldom been reported. In a Finnish population-based cohort in which subjects with previously diagnosed diabetes or CVD disease were excluded, Lakka et al 2 reported that the CVD and overall mortality were more consistently associated with the WHO definition of the MS than with the ATPIII definition. Similarly, in the Third National Health and Nutrition Examination Survey (NHANES III) cohort, the adjusted ORs for heart attack and congestive heart failure were higher when the diagnosis of the MS was based on the WHO definition as compared to when the ATPIII definition was used. 7 However, in that same cohort, the prevalence estimates for stroke were similar for participants with the MS defined by either definition. On the other hand, Marchesini et al 8 suggested that in type 2 diabetics, the MS defined by the ATPIII criteria might be more tightly associated with CVD than the WHO criteria. In contrast to previous findings by Isomaa et al, 21 in that particular study, the prevalence of CVD did not differ among diabetics with or without the WHO MS. Differences in the clinical features of the studied populations may help to explain the discordant results among different studies. Type 2 diabetic participants in the study from Marchesini et al were older (mean age 67 y) and had a higher prevalence HDL cholesterol below the ATPIII cutoff value compared to our cohort (39.0 vs 24.8% and 56.0 vs 25.7% in male and female subjects respectively, compared to 24.8 and 25.7% in male and female subjects, respectively in our cohort). Notably, HDL cholesterol below the ATPIII cutoff value has been recognized as a predictor of CVD. 22 Therefore, differences in the prevalence in a particular population of a single risk factor included in the definition of the MS may have an important impact on the prevalence of the MS (50% in our study vs 70% in Marchesini's study 8 ) and affect the strength of its association with CVD. The importance of the utilization of a particular set of criteria to assess the CVD risk associated with the MS in obese adults is underscored by the nonsignificant concordance between the WHO and ATPIII diagnosis of the MS among subjects with CVD in our cohort. The degree of agreement between the WHO and ATPIII MS definitions among subjects with CVD was not addressed in previous studies comparing the association of the MS and CVD. 2, 7, 8 Supporting the relationship between the MS and CVD, as the number of altered metabolic markers increased so did the degree of alteration of most of the CVD risk factors included in the MS definition. The metabolic score has previously been associated with the severity of coronary artery disease. 18 However, whereas the criteria included in the definition of the MS are weighed equally, our data suggest that among the WHO criteria, blood pressure or a microalbuminuria above the defined threshold may be a more potent risk factor for CVD in obese adults. An elevated blood pressure is a strong risk factor for CVD. 23 It has been suggested that the MS amplifies CV risk associated with high blood pressure. 24 The higher threshold for hypertension used by the WHO definition may possibly help to explain why the WHO definition yielded higher prevalence estimates of CVD than the ATPIII definition in our cohort. In that respect, in Marchesini et al 8 study, univariate logistic regression analysis identified hypertension as the sole WHO criterion significantly associated with CVD in type 2 diabetics. Furthermore, despite Black American men were the ethnic group with the lowest prevalence of the MS in the NHANES III cohort, 10 they present with the highest overall mortality from coronary heart disease. 25 Importantly, black men had the highest prevalence of high blood pressure but the lowest frequencies of large waist, high triglyceride levels, and low high-density lipoprotein cholesterol levels of all ethnic groups in the NHANES III cohort. 10 Microalbuminuria is marker of endothelial dysfunction increasing death risk. 26 Evidence suggests that microalbuminuria may be associated with higher relative risk for fatal and nonfatal CVD than other components of the MS. 21, 27 There is a strong relationship between microalbuminuria and high blood pressure 28 and microalbuminuria may be an indicator of early vascular complications in hypertension. 29 It should be underscored that the association between the individual components of the MS and CVD may vary depending on the clinical setting.
Anderson et al 22 found that the primary predictive ability of MS defined by the ATPIII criteria for coronary artery disease (CAD) was carried almost entirely by high fasting glucose and low HDL cholesterol. However, once CAD was established, fasting plasma glucose in the diabetic range but not any other feature predicted the hazard for myocardial infarction or death during follow-up. The lack of an association between the MS defined by the ATPIII criteria and CVD disease was previously reported in American Indians participating in the Strong Heart Study. 30 Moreover, a recent report suggested that the ATPIII MS is associated with only a marginal increase in cardiovascular mortality. 3 Nonetheless, it can be argued that one explanation for the absence of an association between the MS Obesity, metabolic syndrome and cardiovascular disease J Vidal et al defined by the ATPIII criteria and CVD disease in our cohort is that our study has not adequate power to detect a relationship because our results are based on a total of 25 cases of CVD. Although a low of statistical power can not be ruled out as an explanation for our negative finding, the fact that considering the OGTT data resulted in a significant association between the ATPIII-defined MS and CVD offers yet another explanation. Several studies have shown that the presence of diabetes markedly increases the CVD risk associated with MS. 21, 22 The ATPIII did not include an OGTT as part of the MS ascertainment because of the added inconvenience and cost of OGTT in clinical practice. 6, 31 However, analysis of data derived from NHANES III study showed that the addition of the OGTT data would result in an increase in the overall prevalence of the MS of about 5% in patients over the age of 50 y. 31 Our data show that the addition of the OGTT data to the ATPIII criteria may result not only in an increase in the prevalence estimate of the MS but also in an improvement of the strength of its association with CVD. The larger impact of considering OGTT data on the prevalence of the MS in our cohort (15% increase) could be attributed to the fact that centrally obese individuals are at very high risk of type 2 diabetes compared to populationbased cohorts. 32 It has been shown that both IGT and the postpandrial hyperglycaemia that would define OGTTdiagnosed type 2 diabetes carry increased risk for CVD. 33 Consistently, in our cohort, the modified ATPIII MS was significantly associated with CVD. This finding was further emphasized by the results of logistic regression analysis. Whereas fasting glucose data was not independently associated with CVD, the association became significant when an altered glucose tolerance as assessed from the OGTT was considered. Therefore, based on our and others data, we suggest that adding an OGTT at least in nondiabetic patients with two ATPIII-defined metabolic risk factors may help to better identify obese subjects at high risk for CVD. It has been suggested that the addition of C-reactive protein (CRP) levels as criteria for the MS may also improve its association with CVD. 34 This may be of particular interest because obesity has been suggested as a major determinant of CRP levels in subjects with the MS. 35 Unfortunately, CRP levels were not measured in our cohort. One potential limitation of our study is that it refers to a specific group of obese patients referred to a specialized Obesity Unit. It may be argued that this may result in an overestimation of the prevalence of the MS when compared with general obese population because of the referral bias to medical centres. Nevertheless, the prevalence of the MS in our cohort was similar to the 59.6 and 50.0% reported, respectively, in obese men and women aged 20 y and older who participated in the cross-sectional NHANES III when the ATPIII criteria were applied. 10 Moreover, the prevalence of the MS in our cohort was lower than that reported in two previous studies including either obese subjects seeking treatment 9 or obese women referred for coronary angiography to evaluate suspected myocardial ischaemia. 13 In summary, the present study underscores the importance of evaluating the currently available tools for the identification of individuals at high risk for developing CVD. Our data suggest that for the identification of the MS in obese adults, the use of the WHO criteria might be preferable as they appear to identify a greater number of subjects at risk for CVD. Despite the ATPIII criteria for the MS are easier to apply in clinical practice, our data suggest that in its current formulation the ATPIII-defined MS is not a good marker of CVD in obese adults. However, we suggest that the addition of the OGTT data to the ATPIII criteria may result in an improvement of the strength of its association with CVD. Prospective studies are needed to corroborate these crosssectional findings and better estimate the CVD risk associated with each definition of the MS in obese adults.
